Association of Vascular Endothelial Growth Factor Gene+936C/T Polymorphisms with Breast Cancer: A Meta-analysis

WANG Chunlin; HUANG Shengxin; CHENG Xiaowei; ZHANG Yong

doi:10.3971/j.issn.1000-8578.2013.05.019

Cancer Research on Prevention and Treatment > 2013 > 40(05): 489-494. > DOI: 10.3971/j.issn.1000-8578.2013.05.019

WANG Chunlin, HUANG Shengxin, CHENG Xiaowei, ZHANG Yong. Association of Vascular Endothelial Growth Factor Gene+936C/T Polymorphisms with Breast Cancer: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2013, 40(05): 489-494. DOI: 10.3971/j.issn.1000-8578.2013.05.019

Citation:

PDF (1294 KB)

Association of Vascular Endothelial Growth Factor Gene+936C/T Polymorphisms with Breast Cancer: A Meta-analysis

1.Department of Radiation Oncology, First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China;2.Department of Hepatobility Surgery,The Affiliated Tumor Hospital of Guangxi Medical University

More Information

Received Date: September 11, 2012
Revised Date: December 16, 2012

Graphical Abstract

Abstract

Abstract

Objective To explore the relationship between the polymorphism of VEGF and genetic susceptibility of breast cancer. Methods References were retrieved in PubMed, EMBASE, the Cochrane library, Chinese Biological Medicine Disk.Odds ratio (OR) with 95% confidence interval (CI) was used to assess the strength of this association. All analyses were conducted in Stata12.0. Results A total of 10 case-control studies with 17 713 subjects on VEGF+936C/T were included in this Meta- analysis, significant decreased risks were found in allele model T vs. C: OR(95%CI)=0.90(0.81-0.99); co-dominant model CT vs. CC：OR (95%CI )=0.88(0.78-0.90), TT vs. CC: OR(95%CI)=0.91(0.74-1.12); dominant model TT+CT vs. CC: OR(95%CI )=0.88 (0.78-0.99);recessive model TT vs. CT+CC: OR(95%CI)=0.93 (0.76~1.15) . Conclusion +936C/T polymorphism of the VEGF gene is associated with breast cancer, T allele may be a protective factor.
- Vascular endothelial growth factor (VEGF),
- Single nucleotide polymorphism,
- Breast cancer,
- Meta-analysis

FullText(HTML)

References (38)

References

[1]	Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2):69-90.
[2]	Dumitrescu R, Cotarla I. Understanding breast cancer risk‐where do we stand in 2005?[J]. J Cell Mol Med, 2005, 9(1):208-21.
[3]	Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors[J]. Nat Med, 2003, 9 (6):669-76.
[4]	Schneider BP, Miller KD. Angiogenesis of breast cancer[J]. J Clin Oncol, 2005, 23(8):1782-90.
[5]	Schneider BP, Sledge GW. Drug insight: VEGF as a therapeutic target for breast cancer[J]. Nat Clin Pract Oncol, 2007, 4(3):181-9.
[6]	Krippl P, Langsenlehner U, Renner W, et al. A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk[J]. Int J Cancer, 2003, 106(4):468-71.
[7]	Jin QR, Hemminki K, Enquist K, et al. Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis[J]. Clin Cancer Res, 2005,11(10):3647-53.
[8]	Oliveira C, Loureno GJ, Silva PM, et al. Polymorphisms in the 5'-and 3'-untranslated region of the VEGF gene and sporadic breast cancer risk and clinicopathologic characteristics[J].Tumour Biol, 2011, 32(2):295-300.
[9]	Jacobs EJ, Feigelson HS, Bain EB, et al. Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort[J]. Breast Cancer Res, 2006, 8(2):R22.
[10]	Kataoka N, Cai Q, Wen W, et al. Population-based case-control study of VEGF gene polymorphisms and breast cancer risk among Chinese women[J]. Cancer Epidemiol Biomarkers Prev, 2006, 15(6):1148- 52.
[11]	Jakubowska A, Jaworska K, Cybulski C, et al. Do BRCA1 modifiers also affect the risk of breast cancer in non-carriers? [J]. Eur J Cancer, 2009, 45(5):837-42.
[12]	Lin GT, Tseng HF, Yang CH, et al. Combinational polymorphisms of seven CXCL12-related genes are protective against breast cancer in Taiwan[J]. OMICS, 2009, 13(2):165-72.
[13]	Balasubramanian SP, Cox A, Cross SS, et al. Influence of VEGF-A gene variation and protein levels in breast cancer susceptibility and severity[J]. Int J Cancer, 2007, 121(5):1009-16.
[14]	Pharoah PD, Tyrer J, Dunning AM, et al. Association between common variation in 120 candidate genes and breast cancer risk[J]. PLoS Genet, 2007, 3(3):e42.
[15]	Rodrigues P, Furriol J, Tormo E, et al. The single-nucleotide polymorphisms +936 C/T VEGF and -710 C/T VEGFR1 are associated with breast cancer protection in a Spanish population [J]. Breast Cancer Res Treat, 2012, 133(2):769-78.
[16]	Nakamura M, Abe Y, Tokunaga T. Pathological significance of vascular endothelial growth factor A isoform expression in human cancer[J]. Pathol Int 2002, 52(5-6):331-9.
[17]	Vincenti V, Cassano C, Rocchi M, et al. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3[J]. Circulation, 1996, 93(8):1493-5.
[18]	Yang B, Cross DF, Ollerenshaw M, et al. Polymorphisms of the vascular endothelial growth factor and susceptibility to diabetic microvascular complications in patients with type 1 diabetes mellitus[J]. J Diabetes Complications, 2003, 17(1): 1-6.
[19]	Shahbazi M, Fryer AA, Pravica V, et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection[J]. J Am Soc Nephrol, 2002, 13(1): 260-4.
[20]	Mohammadi M, Ollier W E R, Hutchinson IV. A functional association study of VEGF gene promoter polymorphisms with VEGF expression by stimulated pbm cells[J]. Human Immunology, 2003, 64: S125.
[21]	Awata T, Inoue K, Kurihara S, et al. A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes[J]. Diabetes, 2002, 51(5): 1635-9.
[22]	Renner W, Kotschan S, Hoffmann C, et al. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels[J]. Journal of vascular research, 2000, 37(6): 443-8.
[23]	Tahara T, Shibata T, Nakamura M, et al. Effect of polymorphisms in the 3' untranslated region (3'-UTR) of vascular endothelial growth factor gene on gastric cancer and peptic ulcer diseases in Japan [J]. Mol Carcinog, 2009, 48(11):1030-7.
[24]	Lin CC, Wu HC, Tsai FJ, et al. Vascular endothelial growth factor gene-460C/T polymorphism is a biomarker for prostate cancer[J]. Urology, 2003, 62(2):374-7.
[25]	Zhai R, Liu G, Asomaning K, et al. Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma risk[J]. Carcinogenesis, 2008, 29(12):2330-4.
[26]	Ero〖AKgˇD〗lu A, ztürk A, Cam R, et al. Vascular endothelial growth factor gene 936 C/T polymorphism in breast cancer patients[J]. Med Oncol, 2008, 25(1):54-5.
[27]	Katalinic D, Plestina S. Vascular endothelial growth factor (VEGF) 936C/T gene polymorphism is a risk factor for invasive ductal carcinoma of the breast in a sample of Croatian woman[J]. EJC Supplements, 2009, 7（2）:149.
[28]	Gu D, Wang M. VEGF 936C> T polymorphism and breast cancer risk: evidence from 5,729 cases and 5,868 controls[J]. Breast Cancer Res Treat, 2011, 125(2): 489-93.
[29]	Jakubowska A, Gronwald J, Menkiszak J, et al. The VEGF-936C/T 3'UTR polymorphism reduces BRCA1-associated breast cancer risk in Polish women[J]. Cancer Lett, 2008, 262(1):71-6.
[30]	Hsiao PJ, Lu MY, Chiang FY, et al. Vascular endothelial growth factor gene polymorphisms in thyroid cancer[J]. J Endocrinol, 2007, 195(2):265-70.
[31]	Hsueh C, Lin JD, Wu IC, et al. Vascular endothelial growth factors and angiopoietins in presentations and prognosis of papillary thyroid carcinoma[J]. J Surg Oncol, 2011, 103(5):395-9.
[32]	Dassoulas K, Gazouli M, Rizos S, et al. Common polymorphisms in the vascular endothelial growth factor gene and colorectal cancer development, prognosis, and survival[J]. Mol Carcinogenesis, 2009, 48(6):563-9.
[33]	Giacalone A, Montalto G, Giannitrapani L, et al. Association between single nucleotide polymorphisms in the cyclooxygenase-2, tumor necrosis factor-α, and vascular endothelial growth factor-A genes, and susceptibility to hepatocellular carcinoma[J]. OMICS, 2011, 15(3):193-6.
[34]	Guan X, Zhao H, Niu J,et al. The VEGF -634G>C promoter polymorphism is associated with risk of gastric cancer[J]. BMC Gastroenterol, 2009, 9:77.
[35]	Ajaz S, Khaliq S, Abid A, et al. Association of a single-nucleotide polymorphism in the promoter region of the VEGF gene with the risk of renal cell carcinoma[J]. Genet Test Mol Biomarkers, 2011, 15(9):653-7.
[36]	Sfar S, Saad H, Mosbah F, et al. Synergistic effect and VEGF/HSP70-hom haplotype analysis: Relationship to prostate cancer risk and clinical outcome[J]. Human Immunol, 2010, 71(4):377-82.
[37]	Cao C, Fang JJ, Ying T, et al. Vascular endothelial growth factor +936C/T and +405G/C polymorphisms and cancer risk: a meta-analysis[J]. Arch Med Res, 2010, 41(7):548-57.
[38]	Xu B, Li JM, Tong N, et al. VEGFA + 936C>T polymorphism and cancer risk: a meta-analysis[J]. Cancer Genet Cytogenet, 2010, 198(1):7-14.

Cited By

Cited by

Periodical cited type(4)

1.	龚解其，沈卫星，陆欢华. 肝细胞癌肿瘤微环境细胞毒性T细胞PD-1的表达及其临床意义. 临床和实验医学杂志. 2024(01): 5-9 .
2.	陈晓晓，刘浩楠，韩正祥，潘迪，渠琬溪，冯守信. 外周血嗜酸性粒细胞计数对中晚期肝癌患者免疫治疗疗效的预测价值. 现代肿瘤医学. 2024(11): 2025-2032 .
3.	曾海荣，黄丹，张建军，华海琴. 外周血CD4~+CD25~+、CD8~+CD28~+调节性T细胞水平对早期宫颈癌患者腹腔镜根治术后预后的预测价值. 中国临床新医学. 2024(07): 800-805 .
4.	陈锦添，陈从其，李智强，郑元振. 前列腺癌患者PD-1水平与肿瘤分期的关系. 国际泌尿系统杂志. 2024(05): 815-818 .

Other cited types(0)

Get Citation

PDF

XML

Article views (1899) PDF downloads (558) Cited by(4)

Turn off MathJax

Article Contents

Abstract

References

Association of Vascular Endothelial Growth Factor Gene+936C/T Polymorphisms with Breast Cancer: A Meta-analysis

Abstract

References

Cited by

Periodical cited type(4)

Other cited types(0)

Catalog

Contact Us

Association of Vascular Endothelial Growth Factor Gene+936C/T Polymorphisms with Breast Cancer: A Meta-analysis

Abstract

References

Cited by

Periodical cited type(4)

Other cited types(0)

Catalog

Contact Us

Export File

Citation

Format

Content